Skip to main content
SpringerLink
Log in

Principles of Chemotherapy, Targeted Therapy, and Immunotherapy in Gynaecological Malignancies

  • Chapter
  • First Online:
Fundamentals in Gynaecologic Malignancy

  • 463 Accesses

Abstract

In the management of cancer, both surgery and radiotherapy are essential local forms of treatments that are directed towards primary tumors and any loco-regional disease. Chemotherapy is a systemic modality and can treat distant metastases. Chemotherapy is used to improve the prognosis in majority of cancers, but is curative only in the minority of cancers. Chemotherapy is well known to cure lymphomas, leukemias, testicular cancers, and choriocarcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.

    Article  CAS  Google Scholar 

  2. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141:1117–34.

    Article  CAS  Google Scholar 

  3. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability: an evolving hallmark of cancer. Nat Rev Mol Cell Biol. 2010;11:220–8.

    Article  CAS  Google Scholar 

  4. Skipper HE. Kinetics of mammary tumor cell growth and implications for therapy. Cancer. 1971;28:1479–99.

    Article  CAS  Google Scholar 

  5. Norton LA. A Gompertzian model of human breast cancer growth. Cancer Res. 1988;48:7067–71.

    CAS  Google Scholar 

  6. Raguz S, Yague E. Resistance to chemotherapy: new treatments and novel insights into an old problem. Br J Cancer. 2008;99:387–91.

    Article  CAS  Google Scholar 

  7. Gerlinger M, Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer. 2010;103:1139–43.

    Article  CAS  Google Scholar 

  8. Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to the spontaneous mutation rate. Cancer Treat Rep. 1979;63:1727–33.

    CAS  Google Scholar 

  9. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer InterGroup. J Clin Oncol. 2009;27:1419–25.

    Article  CAS  Google Scholar 

  10. Tan DS-W, Gerlinger M, The B-T, et al. Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference. Eur J Cancer. 2010;46:2166–77.

    Article  CAS  Google Scholar 

  11. Sakai S, Swisher EM, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008;451:1116–21.

    Article  CAS  Google Scholar 

  12. Cress RD, O’Malley CD, Leiserowitz GS, et al. Patterns of chemotherapy use for women with ovarian cancer: a population based study. J Clin Oncol. 2003;21:1530–5.

    Article  Google Scholar 

  13. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21:1431–9.

    Article  CAS  Google Scholar 

  14. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24:2699–707.

    Article  Google Scholar 

  15. Siemann DW, Horsman MR. Modulation of the tumor vasculature and oxygenation to improve therapy. Pharmacol Ther. 2015;153:107–24.

    Article  CAS  Google Scholar 

  16. Borner M, Scheithauer W, Twelves C, et al. Answering patients’ needs: oral alternatives to intravenous therapy. Oncologist. 2001;4:12.

    Article  Google Scholar 

  17. Dedrick RL, Myers CE, Bungay PM, et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62:1–9.

    CAS  Google Scholar 

  18. Markman M. Intraperitoneal therapy of ovarian cancer. Semin Oncol. 1998;25:356–60.

    CAS  Google Scholar 

  19. Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res ClinOncol. 1992;118:547–50.

    Article  CAS  Google Scholar 

  20. Rocha-Lima CM, Soares HP, Raez LE, Singal R. EGFR targeting of solid tumors. Cancer Control. 2007;14(3):295–304.

    Article  Google Scholar 

  21. Wiezorek J, Holland P, Graves J. Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res. 2010;16(6):1701–8.

    Article  CAS  Google Scholar 

  22. Alberts DS, Marth C, Alvarez RD, et al. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. Gynecol Oncol. 2008;109(2):174–81.

    Article  CAS  Google Scholar 

  23. Giuntoli RL II, Webb TJ, Zoso A, et al. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res. 2009;29(8):2875–84.

    CAS  Google Scholar 

  24. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2007;25:5165–71.

    Article  CAS  Google Scholar 

  25. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25(33):5180–6.

    Article  CAS  Google Scholar 

  26. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008;26(1):76–82.

    Article  CAS  Google Scholar 

  27. Aghajanian C, Sill MW, Darcy KM, et al. A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group (GOG) study. J Clin Oncol. 2009;27(15_Suppl):5531.

    Article  Google Scholar 

  28. Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27(7):1069–74.

    Article  CAS  Google Scholar 

  29. Faried LS, Faried A, Kanuma T, et al. Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: a potential biomarker and molecular target therapy. Mol Carcinog. 2008;47(6):446–57.

    Article  CAS  Google Scholar 

  30. Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control. 2009;16(1):8–13.

    Article  Google Scholar 

  31. Slomovitz BM, Lu KH, Johnston T, et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010;116(23):5415–9.

    Article  CAS  Google Scholar 

  32. Miwa M, Masutani M. PolyADP-ribosylation and cancer. Cancer Sci. 2007;98(10):1528–35.

    Article  CAS  Google Scholar 

  33. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123–34.

    Article  CAS  Google Scholar 

  34. Press JZ, De Luca A, Boyd N, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer. 2008;8:17.

    Article  Google Scholar 

  35. Coley WB. The treatment of malignant tumours by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci. 1893;105:487.

    Article  Google Scholar 

  36. Alberts DS, Hannigan EV, Liu PY, et al. Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: an intergroup study. Gynecol Oncol. 2006;100(1):133–8.

    Article  CAS  Google Scholar 

  37. Verheijen RH, Massuger LF, Benigno BB, et al. Phase III trial of intraperitoneal therapy with yttrium90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol. 2006;24(4):571–8.

    Article  CAS  Google Scholar 

  38. Berek J, Taylor P, McGuire W, Smith LM, Schultes B, Nicodemus CF. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol. 2009;27(3):418–25.

    Article  CAS  Google Scholar 

  39. Sabbatini P. Consolidation therapy in ovarian cancer: a clinical update. Int J Gynecol Cancer. 2009;19(Suppl 2):S35–9.

    Article  Google Scholar 

  40. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643–7.

    Article  Google Scholar 

  41. Odunsi K, Qian F, Matsuzaki J, et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A. 2007;104(31):12837–42.

    Article  CAS  Google Scholar 

  42. Diefenbach CS, Gnjatic S, Sabbatini P, et al. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin Cancer Res. 2008;14(9):2740–8.

    Article  CAS  Google Scholar 

  43. Hernando JJ, Park TW, Fischer HP, et al. Vaccination with dendritic cells transfected with mRNA encoded folate-receptor-alpha for relapsed metastatic ovarian cancer. Lancet Oncol. 2007;8(5):451–4.

    Article  Google Scholar 

  44. Czerniecki BJ, Koski GK, Koldovsky U, et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res. 2007;67(4):1842–52.

    Article  CAS  Google Scholar 

  45. Gong J, Apostolopoulos V, Chen D, et al. Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells. J Immunol. 2000;101(3):316–24.

    Article  CAS  Google Scholar 

  46. Sabbatini PJ, Ragupathi G, Hood C, et al. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin Cancer Res. 2007;13(14):4170–7.

    Article  CAS  Google Scholar 

  47. Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12(20 Pt 1):6106–15.

    Article  CAS  Google Scholar 

  48. Chekmasova AA, Brentjens RJ. Adoptive T cell immunotherapy strategies for the treatment of patients with ovarian cancer. Discov Med. 2010;9(44):62–70.

    Google Scholar 

  49. Hatfield P, Merrick AE, West E, et al. Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy. J Immunother. 2008;31(7):620–32.

    Article  Google Scholar 

  50. Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48:434–52.

    Article  CAS  Google Scholar 

  51. Zhou G, Sprengers D, Boor PPC, Doukas M, Schutz H, Mancham S, Pedroza-Gonzalez A, Polak WG, de Jonge J, Gaspersz M, et al. Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in hepatocellular carcinomas. Gastroenterology. 2017;153:1107–19.

    Article  CAS  Google Scholar 

  52. Salmaninejad A, Valilou SF, Shabgah AG, Aslani S, Alimardani M, Pasdar A, Sahebkar A. PD-1/PD-L1 pathway: basic biology and role in cancer immunotherapy. J Cell Physiol. 2019;234:16824–37.

    Article  CAS  Google Scholar 

  53. Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38:1–10.

    Article  CAS  Google Scholar 

  54. Makker V, Taylor MH, Aghajanian C, Oaknin A, Mier J, Cohn AL, Romeo M, Bratos R, Brose MS, DiSimone C, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol. 2020;38:2981–92.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Dr. Bhubaneswar Borooah Cancer Institute (A Unit of Tata Memorial Centre, Mumbai), Guwahati, Assam, India

    Satya Sadhan Sarangi

  2. ACTREC (Advanced Centre for Treatment, Research and Education in Cancer), Navi Mumbai, Maharashtra, India

    Sudeep Gupta

  3. Department of Gynaecologic Oncology, Dr. Bhubaneswar Borooah Cancer Institute (A Unit of Tata Memorial Centre, Mumbai), Guwahati, Assam, India

    Amal Chandra Kataki

Authors
  1. Satya Sadhan Sarangi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sudeep Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amal Chandra Kataki
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Gynaecologic Oncology, Dr Bhubaneswar Borooah Cancer Institute (A unit of Tata Memorial Centre, Mumbai), Guwahati, Assam, India

    Amal Chandra Kataki

  2. Department of Gynaecologic Oncology, Dr Bhubaneswar Borooah Cancer Institute (A unit of Tata Memorial Centre, Mumbai), Guwahati, Assam, India

    Debabrata Barmon

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Sarangi, S.S., Gupta, S., Kataki, A.C. (2022). Principles of Chemotherapy, Targeted Therapy, and Immunotherapy in Gynaecological Malignancies. In: Kataki, A.C., Barmon, D. (eds) Fundamentals in Gynaecologic Malignancy. Springer, Singapore. https://doi.org/10.1007/978-981-19-5860-1_7

Download citation

  • DOI: https://doi.org/10.1007/978-981-19-5860-1_7

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-19-5859-5

  • Online ISBN: 978-981-19-5860-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation